Condition: Heart Failure With Preserved Ejection Fraction · Sponsor: Rivus Pharmaceuticals, Inc.
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo. Two dose levels will be administered in sequential order (150 mg daily followed by 300 mg daily), each for 20 days, to reach the third and highest dose of 450 mg daily if safety and tolerability are demonstrated at the lower 2 preceding doses. Administration of the 450 mg high dose will continue for a total of 94 days, with a safety follow-up visit within \~14 days of the last dose.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| National Heart Institute | Beverly Hills, California, United States | — |
| Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center | Torrance, California, United States | — |
| New Generation of Medical Research | Hialeah, Florida, United States | — |
| Broward Research Center | Pembroke Pines, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| The University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Johns Hopkins University | Baltimore, Maryland, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Saint Luke's Mid America Heart Institute | Kansas City, Missouri, United States | — |
| Weill Cornell Medicine | New York, New York, United States | — |
| Wake Forest | Winston-Salem, North Carolina, United States | — |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05284617